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Background: The transcription factor Ecotropic Virus Integration site 1 (EVI1) regulates cellular proliferation,
differentiation, and apoptosis, and its overexpression contributes to an aggressive course of disease in myeloid
leukemias and other malignancies. Notwithstanding, knowledge about the target genes mediating its biological
and pathological functions remains limited. We therefore aimed to identify and characterize novel EVI1 target genes
in human myeloid cells.
Methods: U937T_EVI1, a human myeloid cell line expressing EVI1 in a tetracycline regulable manner, was subjected
to gene expression profiling. qRT-PCR was used to confirm the regulation of membrane-spanning-4-domains
subfamily-A member-3 (MS4A3) by EVI1. Reporter constructs containing various parts of the MS4A3 upstream region
were employed in luciferase assays, and binding of EVI1 to the MS4A3 promoter was investigated by chromatin
immunoprecipitation. U937 derivative cell lines experimentally expressing EVI1 and/or MS4A3 were generated by retroviral
transduction, and tested for their tumorigenicity by subcutaneous injection into severe combined immunodeficient mice.
Results: Gene expression microarray analysis identified 27 unique genes that were up-regulated, and 29 unique genes
that were down-regulated, in response to EVI1 induction in the human myeloid cell line U937T. The most strongly
repressed gene was MS4A3, and its down-regulation by EVI1 was confirmed by qRT-PCR in additional, independent
experimental model systems. MS4A3 mRNA levels were also negatively correlated with those of EVI1 in several
published AML data sets. Reporter gene assays and chromatin immunoprecipitation showed that EVI1 regulated MS4A3
via direct binding to a promoter proximal region. Experimental re-expression of MS4A3 in an EVI1 overexpressing cell
line counteracted the tumor promoting effect of EVI1 in a murine xenograft model by increasing the rate of apoptosis.
Conclusions: Our data reveal MS4A3 as a novel direct target of EVI1 in human myeloid cells, and show that its
repression plays a role in EVI1 mediated tumor aggressiveness.
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Overexpression of the Ecotropic Virus Integration site 1
(EVI1) gene, which has been observed in subsets of pa-
tients with acute myeloid leukemia (AML) [1-4], myelodys-
plastic syndromes (MDS) [5-7], chronic myeloid leukemia
(CML) [8-10], and certain solid tumors [11-14], is often as-
sociated with poor therapy response and shortened survival* Correspondence: rotraud.wieser@meduniwien.ac.at
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unless otherwise stated.[1-4,7,9,11,12,15,16]. In mouse bone marrow transduction/
transplantation models, experimental expression of Evi1
led to development of an MDS-like disease [17], or to
AML-like disease when co-expressed with other onco-
genes [18,19]. It also enhanced the growth of xenograft tu-
mors in severe combined immunodeficient (SCID) mice
[20]. In vitro, EVI1 stimulated cellular proliferation and
inhibited differentiation and apoptosis in some experi-
mental models [14,17,20-29], but evoked opposite responses
in others [17,29-37], indicating that the consequences of
EVI1 overexpression may be influenced by cell lineage,
maturation stage, cooperating molecular events, and/orhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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biological functions predominantly by regulating gene
transcription, and recently large-scale approaches have
been applied to identify its target genes in ovarian cancer
and murine myeloid cell lines [38,39]. A limited number
of genes were shown to be regulated by EVI1 in a direct
manner and to contribute to some of its biological effects,
e.g., Gata2 [24], Pbx1 [40], Pten [41], Gpr56 [42], miR-1-2
[43], miR-9 [44], miR-124 [45,46], and miR-449A [47]. In
light of the multitude of cellular responses to EVI1, how-
ever, its target genes and mechanisms of action are still far
from completely understood.
The membrane-spanning 4-domains subfamily A mem-
ber 3 (MS4A3) gene was expressed in specific subsets of
hematopoietic cells, including myeloid precursors, baso-
philic granulocytes, and CD34-positive hematopoietic
stem and progenitor cells induced to differentiate in vitro
by exposure to granulocyte colony stimulating factor
(G-CSF) [48-50]. MS4A3 was present in a complex with
cyclin-dependent kinase 2 (CDK2) and kinase-associated
phosphatase (KAP), which inactivates CDK2 by dephos-
phorylation of Thr160 [50]. MS4A3 stimulated the en-
zymatic activity of KAP, and caused cell cycle arrest when
expressed in human myeloid U937 cells in a regulable
manner [50,51].
In the present study, we found that MS4A3 was re-
pressed by EVI1 in several experimental model systems.
This repression was mediated by direct binding of EVI1
to a proximal region in the MS4A3 promoter, and was
necessary for the tumor promoting effects of EVI1 in a
murine xenograft model.
Results
MS4A3 is repressed strongly and rapidly in response to
induction of EVI1
We have previously established U937T_EVI1-HA clones
E10 and E14, which express an HA epitope-tagged version
of the human EVI1 cDNA in a tetracycline (tet) repress-
ible manner in the background of the human myeloid cell
line U937 [34]. In E10 and E14 cells, expression of the
EVI1 protein is strongly induced as early as 12 h after tet
withdrawal, is sustained for at least 120 h, and its peak
levels are comparable to those in HNT-34 cells [34],
which express endogenous EVI1 due to a rearrangement
of its gene locus at 3q26 [52]. In order to identify genes
whose mRNA levels were altered rapidly in response to in-
duction of EVI1, E10 and E14 cells were cultured in the
absence or presence of tet for 6, 12, 24, and 48 h, RNA
was extracted, converted to cRNA, and hybridized to Hu-
man Genome U133 Plus 2.0 arrays (Affymetrix). As con-
trols, parental U937T cells and empty vector transfected
U937T_vec (clone P2) cells that had been incubated with
or without tet for 48 h were processed in the same man-
ner. Tet withdrawal affected gene expression patterns notonly in EVI1-expressing, but also in control cells [53].
Consequently, only those genes were considered to be reg-
ulated by EVI1 whose mRNA levels changed at least 2-fold
48 h after tet withdrawal in both E10 and E14 cells, and
whose induction or repression at this time point exceeded
any background effects observed in either U937T or P2
cells as described in the Methods section. According to
these criteria, 56 unique genes were found to be responsive
to EVI1: 27 genes were up-, and 29 genes were down-
regulated subsequent to the induction of this transcription
factor (Figure 1A). Gene ontology (GO) analysis revealed
significant enrichment of the terms “cytokine biosynthetic
process” and “regulation of apoptosis” among the EVI1-
regulated genes (Additional file 1: Table S1). The gene
most strongly induced by EVI1 in this system was CD52,
which has previously been shown to be up-regulated by
EVI1 and proposed as an immunotherapeutic target for
EVI1-positive leukemia [54]. On the other hand, the most
strongly (~16-fold) repressed gene was MS4A3, which has
been reported as a negative regulator of the mitotic cycle
of hematopoietic cells [50], and was also strongly repressed
in response to inducible ectopic expression of Evi1 in pri-
mary murine hematopoietic cells [29]. Even though a re-
gion ~4 kb from the transcriptional start site of the murine
Ms4a3 gene was found to be bound by EVI1 in a ChiP-seq
screen [39], the precise mechanistic basis and biological
consequences of the repression of MS4A3 by EVI1 have so
far not been investigated.
To corroborate the microarray results, RNA extracted
from U937T_EVI1-HA and U937T_vec cells maintained
in the presence or absence of tet for 6 to 48 h was sub-
jected to reverse transcriptase qRT-PCR. These experi-
ments confirmed that MS4A3 was repressed strongly,
rapidly, and specifically upon induction of EVI1 (Figure 1B).
Similarly, MS4A3 was significantly down-regulated in
U937_EVI1 [20] and HL-60_Evi1 [55] cells, which experi-
mentally express EVI1 in a constitutive manner, as com-
pared to the respective empty vector transduced control
cells (Figure 1C, D). Conversely, siRNA mediated knock-
down of EVI1 in UCSD-AML1 cells, which express high
endogenous levels of this gene [56], led to up-regulation
of MS4A3 (Figure 1E). In additional support of the regu-
latory relationship between EVI1 and MS4A3, analysis
of gene expression omnibus (GEO) microarray data sets
GSE35159 [54], GSE6891 [57], GSE14471 [58], and GSE35784
[59] revealed that human myeloid cell lines and primary
AML patient samples with high EVI1 mRNA levels ex-
hibited low expression ofMS4A3 and vice versa (Figure 1F,
Table 1).
EVI1 regulates MS4A3 through a promoter proximal
region
To test whether EVI1 would affect the MS4A3 promoter in
a direct manner, and to identify potential EVI1-responsive
Figure 1 MS4A3 is strongly repressed by EVI1 in human myeloid cells. A) Heatmap summarizing expression changes of 56 genes affected
by induction of EVI1 in U937T_EVI1-HA cells (clones E10 and E14) as determined by microarray analyses at different time points after transfer to
tetracycline (tet) free media. Parental U937T cells and U937T_vec (clone P2) cells incubated with or without tet for 48 h were used as controls.
Log2 transformed expression changes relative to cultures maintained in the presence of tet (red, upregulated; blue, downregulated) are shown in
descending order. B) qRT-PCR confirmed repression of MS4A3 in U937T_EVI1-HA, but not U937T_vec cells after tet withdrawal. C, D) qRT-PCR
showing EVI1-mediated down-regulation of MS4A3 in U937 (C) or HL-60 (D) cells constitutively expressing ectopic EVI1. E) qRT-PCR showing
induction of MS4A3 after siRNA mediated down-regulation of EVI1 in UCSD-AML1 cells. Data in B-E represent means + SEMs from at least
three independent biological replicate experiments. F) MS4A3 mRNA levels in a panel of 12 human myeloid cell lines (8 with low and 4
with high EVI1 expression) represented in GEO data set GSE35159 [54]. *p < 0.05; **p < 0.01; ***p < 0.001 (Student’s t-test, two-tailed). The
induction of MS4A3 after knock-down of EVI1 in UCSD-AML1 cells was not significant, but an at least 1.8-fold up-regulation was observed
in four out of four independent biological replicate experiments.
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proximately 3.2 kb fragment representing the upstream
region of the human MS4A3 gene was cloned into the
promoterless Gaussia luciferase reporter vector, pGluc
basic, to yield pMS4A3(-3213/+11)/pGluc. 5′ deletion
variants of this vector were prepared in an analogousTable 1 Negative association between EVI1 and MS4A3 mRNA
Data set Cutoff # EVI1high # EVI1low
GSE6891 C1 5.97 18 229
GSE6891 C2 6.16 12 202
GSE14471 8.61 9 102
GSE35784 5.66 21 109
Bootstrap analysis was performed on GEO microarray data sets GSE14471 [58], GSE
patient cohorts (C1, C2). For each of the four patient cohorts, cutoff values defining
described in Materials and Methods. The respective groups of EVI1high patients wer
patients. Cutoff, log2 intensity of EVI1 expression defining EVI1
high versus EVI1low pa
EVI1high and randomly permuted EVI1low patients; SD, standard deviation of M; Z, Zmanner. The reporter plasmids were transfected into
U937 cells, along with an EVI1 expression vector or empty
vector as a control. As shown in Figure 2A, all MS4A3 re-
porter constructs, including pMS4A3(-268/-1)/pGluc, were
repressed by EVI1, suggesting that EVI1 acted directly on
theMS4A3 promoter, and that the 268 proximal base pairslevels in primary samples from AML patients
% EVI1high M SD Z P-Value
7.3 -1.36 0.40 3.37 7.4E-04
5.6 -1.16 0.54 2.16 3.1E-02
8.1 -1.86 0.73 2.56 1.0E-02
16.2 -1.01 0.36 2.84 4.5E-03
35784 [59], and GSE6891 [57], the latter of which consists of two independent
high (EVI1high) versus low (EVI1low) EVI1 expression were determined as
e compared to 10.000 randomly sampled, equally sized groups of EVI1low
tients; M, mean difference of log2 transformed MS4A3 expression between
-score of the sampling distribution (Z = -M/SD).
Figure 2 EVI1 regulates MS4A3 by directly binding to a proximal element in its promoter. A) Luciferase assays with MS4A3 promoter
deletion constructs. The MS4A3 5′ region, starting from -3213 relative to the transcription start site, and several 5′ deletion variants thereof were
cloned into the promoterless Gaussia luciferase reporter vector, pGluc basic. Reporter plasmids and either an EVI1 expression vector (+EVI1; black
bars) or empty vector as a control (-EVI1; grey bars) were transfected into U937 cells, and luciferase activity was measured from cell supernatants
two days later. pGluc basic without any MS4A3 5′ sequences was used as negative control. B) Similar experiments were performed using some of
the above described reporter plasmids with the HSV tk basal promoter inserted between the MS4A3 5′ regions and the luciferase gene of pGluc
basic. Data in A) and B) represent means + SEMs from three independent biological replicate experiments. C) ChIP assays were performed on
U937_EVI1 and U937_vec cells using two different EVI1 antibodies (AB1, sc-8707X, Santa Cruz; AB2, C50E12, Cell Signaling). Primers used for ChIP
PCR amplified a region in the proximal MS4A3 promoter as indicated by the arrows in the upper panel. IgG, negative control using nonspecific
IgG; no AB, negative control without antibody; +, input DNA (positive control); -, H2O (negative) PCR control.
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gion from the full length reporter vector yielded pMS4A3
(-3213/-279)/pGluc. The absence of repression by EVI1
indicated that the proximal region of the MS4A3 pro-
moter was not only sufficient, but also necessary for the
response to EVI1 (Figure 2A). To ensure that the loss of
regulation by EVI1 was not simply a consequence of the
removal of basal promoter elements, and therefore to ageneral expression defect in pMS4A3(-3213/-279)/pGluc,
equivalent vectors were generated, but with the HSV tk
promoter inserted between the MS4A3 upstream regions
and the pGluc sequences. As shown in Figure 2B, pMS4A3
(-3213/+11)/tk/pGluc, containing the 3.2 kb MS4A3 up-
stream sequence in front of the tk promoter, was re-
pressed by EVI1. An even stronger effect was observed
with pMS4A3(-268/-1)/tk/pGluc, which comprised only
Heller et al. Journal of Hematology & Oncology  (2015) 8:28 Page 5 of 14the EVI1-responsive proximal promoter region, whereas
removal of this region in pMS4A3(-3213/-279)/tk/pGluc
reduced the repression by EVI1 to basal levels.
To confirm that EVI1 bound to the relevant region of
the MS4A3 promoter in intact cells, chromatin immuno-
precipitation (ChIP) was performed (Figure 2C). Two
different EVI1 antibodies, but not an isotype control
antibody, recovered substantial amounts of DNA that
could be amplified with oligonucleotide primers specific
for the proximal region of the MS4A3 promoter from
U937_EVI1 cells. Confirming the specificity of the assay,
no such enrichment was observed when U937_vec cells
were used.
In summary, these data suggest that EVI1 regulates ex-
pression of MS4A3 by directly binding to a DNA element
located upstream of and in close vicinity to its transcrip-
tional start site, and that this region is both necessary and
sufficient to mediate repression by EVI1.
Experimental re-expression of MS4A3 in EVI1-positive cells
counteracts the acceleration of tumor growth effected by
EVI1
Having identified MS4A3 as a gene that was regulated by
EVI1 in a direct manner and in several independent ex-
perimental systems, we next asked whether repression of
MS4A3 contributed to cellular phenotypes elicited by
EVI1. To this end, the human MS4A3 cDNA was cloned
into pMIA-II, a retroviral vector containing the fluorescent
marker gene Ametrine. U937_vec and U937_EVI1 cells
were infected with empty pMIA-II as a control or with
pMIA-II_MS4A3, yielding the cell lines U937_vec_vec,
U937_vec_MS4A3, U937_EVI1_vec, and U937_EVI1_Figure 3 Ectopic expression of MS4A3 counteracts the tumor promot
analysis of U937_vec_vec (red bars), U937_vec_MS4A3 (blue bars), U937_EV
propidium iodide staining of nuclei isolated from cells growing exponentia
independent biological replicate experiments. B) U937_vec_vec (red line), U
EVI1_MS4A3 (black line) cells were subcutaneously injected into SCID mice
indicated time points. *p <0.05; **p <0.01; ***p <0.001; two-way ANOVA an
U937_vec_MS4A3 vs. U937_EVI1_MS4A3; c, U937_EVI1_vec vs U937_EVI1_MMS4A3. Cells were sorted for Ametrine positivity, and the
expression of MS4A3 according to the expected pattern
was verified by immunofluorescence analysis (Additional
file 2: Figure S1). Since EVI1 had previously been shown to
inhibit myelomonocytic differentiation in this experimental
model system [20], the possibility that re-expression of
MS4A3 may alleviate this effect was explored. U937_vec_
vec, U937_vec_MS4A3, U937_EVI1_vec, and U937_EVI1_
MS4A3 cells were treated with 25-OH Vitamin D3 or
solvent (EtOH) for 5 days, stained with CD11b or iso-
type control antibody, and subjected to flow cytome-
try. The results of these experiments corroborated the
notion that EVI1 inhibited myelomonocytic differenti-
ation, yet MS4A3 had no effect on this process either
in the absence or in the presence of EVI1 (Additional
file 3: Figure S2).
Next, we asked whether EVI1 and/or MS4A3 would
affect cellular proliferation in vitro or in vivo. Even
though constitutive experimental expression of neither
of these genes altered the cell cycle distribution of U937
cells in vitro in a significant manner (Figure 3A), EVI1
strongly and significantly enhanced the growth of tumors
derived from these cells after subcutaneous injection into
SCID mice, and re-expression of MS4A3 abolished this ef-
fect (Figure 3B). Immunohistochemical staining of tumor
sections corroborated both the down-regulation of en-
dogenous MS4A3 by EVI1 at the protein level, and the
persistent expression of exogenous EVI1 and MS4A3 in
the xenograft tumors (Figure 4). To investigate whether
the observed disparity in tumor growth was attributable to
different rates of proliferation and/or cell death, tumor
sections were stained for the proliferation marker Ki-67ing effect of EVI1 in a murine xenograft model. A) Cell cycle
I1_vec (green bars), and U937_EVI1_MS4A3 (black bars) cells after
lly in suspension culture. Data represent means + SEMs of three
937_vec_MS4A3 (blue line), U937_EVI1_vec (green line), and U937_
(4 animals per cell line) and tumor volume was measured at the
d Bonferroni post-correction. a, U937_vec_vec vs. U937_EVI1_vec; b,
S4A3.
Figure 4 Persistent expression of ectopic EVI1 and MS4A3 in xenograft tumors, and confirmation of down-regulation of endogenous
MS4A3 by EVI1 at the protein level. Immunohistochemical analyses of EVI1 (left panel) and MS4A3 (right panel) in xenograft tumors derived
from U937_vec_vec, U937_vec_MS4A3, U937_EVI1_vec, and U937_EVI1_MS4A3 cells. Scale bar, 100 μm.
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the terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) method. These experiments showed
that all tumors contained large areas that were composed
almost exclusively of Ki-67-positive cells, included high
proportions of mitotic figures, and were interspersed only
with sporadic TUNEL-positive cells (Figure 5A, Additional
file 4: Figure S3A, and data not shown). On the other hand,some fractions of the tumors comprised high proportions,
or consisted almost exclusively, of TUNEL-positive, Ki-67-
negative cells (Figure 5A, Additional file 4: Figure S3B).
The overall percentage of TUNEL positive cells was sig-
nificantly higher in U937_EVI1_MS4A3 tumors than in
U937_EVI1_vec tumors (Figure 5B), suggesting that re-
expression of MS4A3 in EVI1-positive myeloid cells may
slow tumor growth by enhancing the rate of cell death.
Figure 5 MS4A3 enhances apoptosis in EVI1-positive xenograft tumors. A) Whole sections of tumors derived from U937_vec_vec, U937_
vec_MS4A3, U937_EVI1_vec, and U937_EVI1_MS4A3 cells were subjected to immunohistochemical staining for Ki-67 (left panel), or to staining
for double strand breaks using the TUNEL method (right panel). Representative images are shown. Scale bar, 2 mm. B) Bar plot showing mean
percentages + SEMs of TUNEL positive cells in 3 tumors of each of the 4 xenograft groups. *p < 0.05 (Student’s t-test, two-tailed).
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EVI1 is an oncogene whose overexpression is associated
with high aggressiveness of both hematological and solid
tumors [1-4,7,9,11,12,15,16]. Even though this correl-
ation is well established, and the molecular structure,
nuclear localization, and DNA binding ability of EVI1
suggest that it acts as a transcription factor [60], the tar-
get genes and molecular mechanisms through which it
contributes to the emergence and therapy resistance of
malignant diseases are still understood only to a limited
extent. Recently, genome-wide large-scale approaches
have been applied to identify genes regulated by EVI1 in
murine hematopoietic cells and a human ovarian cancer
cell line [29,38,39]. In the present study, we used a com-
plementary approach and searched for genes whose
expression levels changed in response to inducible ex-
pression of EVI1 in a human myeloid cell line. Among 56
bona fide EVI1-regulated genes, the MS4A3 gene, coding
for a member of a family of four-transmembrane proteins,
was repressed most strongly after induction of EVI1.
MS4A3 was also down-regulated in primary murine
hematopoietic cells inducibly expressing Evi1 [29], and its
mRNA levels changed in the expected direction after ma-
nipulation of EVI1 expression in three additional human
myeloid cell line based models (Figure 1 C-E). When
CD34-positive primary human hematopoietic stem and
progenitor cells were differentiated into the granulocytic
lineage in vitro, EVI1 levels decreased [36] while MS4A3
levels increased [50] (and KS, unpublished results). Fur-
thermore, EVI1 expression was negatively correlated with
that of MS4A3 in a panel of human myeloid cell lines
and in primary samples from AML patients (Figure 1F,
Table 1). Reporter gene assays and ChIP showed that
EVI1 regulated MS4A3 by directly binding to the prox-
imal 268 bp of its promoter. ChIP-seq on a murine
leukemic cell line also identified an EVI1 binding site near
the Ms4a3 gene [39], yet at a greater distance from its
transcriptional start site, and the functional significance of
this site was not further investigated. Previous studies have
defined a number of different consensus EVI1 binding
sites [38,39,61-67], but interestingly, none of these sites
was found in the 268 bp region delineated through the lu-
ciferase assays, suggesting that EVI1 has the ability to
recognize DNA motifs in addition to those identified in
these earlier studies.
To date, little is known about the biological functions
of MS4A3. Donato et al reported that inducible expres-
sion of this gene in U937 cells retarded their re-entry
into the cell cycle after release from S-phase arrest [50].
Using a constitutive overexpression approach in the
same cell line, we did not observe any effect of MS4A3
on the cell cycle distribution of asynchronously prolifer-
ating cells (Figure 3A), or on re-entry into the mitotic
cycle of cells synchronized in the same manner asdescribed by Donato et al (JE, unpublished results). Pos-
sible explanations for this divergence are the use of dif-
ferent expression systems and/or different U937 sublines
between the Donato and our own studies. However, add-
itional investigations will be required to resolve this
discrepancy.
The reciprocal expression patterns of EVI1 [36] and
MS4A3 [50] (and KS, unpublished results) during in vitro
differentiation of primary human CD34-positive cells
into the granulocytic lineage raise the possibility that
repression of MS4A3 may contribute to the differenti-
ation inhibiting effect of EVI1 [17,20,29]. However, ectopic
expression of MS4A3 in U937_EVI1 or U937_vec cells
did not affect their differentiation in response to 25-OH
Vitamin D3 (Additional file 3: Figure S2), indicating either
that induction of MS4A3 is a consequence rather than a
cause of myeloid maturation, or that other model systems
are required to reveal a potential differentiation promoting
effect of MS4A3.
A gene expression signature characterizing leukemic
stem and progenitor cells as opposed to the bulk leukemic
population was associated with poor outcome in AML,
and low expression of MS4A3 constituted part of this sig-
nature [68]. MS4A3 was also significantly down-regulated
in a cyclophosphamide-resistant CML cell line as com-
pared to the corresponding parental line (GEO data set
GDS2729 [69]). We therefore asked whether repression
of MS4A3 could play a role in EVI1-mediated drug
resistance of human myeloid leukemic cells [20,27,70], yet
re-expression of MS4A3 in U937_EVI1 cells did not re-
sensitize them to drugs used in the treatment of AML (JE
and SK, unpublished results). Nevertheless, a role for down-
regulation ofMS4A3 in EVI1-induced disease aggressiveness
was obtained in a murine xenograft model, in which tu-
mors formed by U937_EVI1 cells grew significantly faster
than U937_vec tumors, while re-expression of MS4A3
abolished this effect. Interestingly, MS4A3 did not slow
the growth of EVI1-negative U937_vec tumors, suggesting
either that endogenous MS4A3 was expressed at satur-
ating levels in this cell line, or that MS4A3 specific-
ally interfered with tumor growth on the background
of the gene expression pattern evoked by EVI1. The
first possibility would predict that U937_EVI1_MS4A3
and U937_vec_MS4A3 grew at equal rates. The obser-
vation that in fact U937_EVI1_MS4A3 cells formed
significantly smaller tumors than U937_vec_MS4A3
cells discredits the former explanation in favor of the
latter. The in vivo phenotypes of EVI1 and MS4A3 are
also notable in light of the absence of an effect of either of
these genes on cellular proliferation in suspension cultures
in vitro. This suggests that specific aspects of the growth
condition in vivo, e.g., interactions with the tumor micro-
environment, are required for them to reveal their impact
on cell and tumor growth.
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In summary, our data uncover MS4A3, a so far poorly
studied gene, as a novel direct target of EVI1 in myeloid
cells, and show that its repression plays a role in EVI1-
mediated tumor aggressiveness. These results increase
the still fragmentary understanding of the way of action
of EVI1, an oncogene that is of great clinical importance
because its overexpression is associated with poor ther-
apy response in a variety of malignant diseases.
Methods
Cell lines, retroviral transductions, immunofluorescence
analysis, and gene knockdown
Cell lines U937T_EVI1-HA, represented by clones E10
and E14, and U937T_vec, represented by clone P2, have
been described previously [34]. They were cultured in
RPMI 1640 (Life Technologies, Carlsbad, CA, USA) con-
taining 10% fetal bovine serum (FBS; Life Technologies),
0.5 μg/ml puromycin (Sigma-Aldrich, St Louis, MO,
USA), 500 μg/ml hygromycin (PAA, Pasching, Austria),
and 1 μg/ml tetracycline (Sigma-Aldrich) in a humidified
incubator at 37°C and 5% CO2. To induce EVI1 expression,
exponentially growing cells were washed 3 times with
PBS (Life Technologies) and resuspended in growth
media without tetracycline. Control cultures were washed
in the same manner but were resuspended in media with
tetracycline.
Cell lines U937_EVI1, U937_vec [20], HL60_Evi1, and
HL60_vec [55] were grown in RPMI 1640 containing
10% FBS and 1% Penicillin/Streptomycin/Glutamine
(PSG; Life Technologies). The coding sequence of the hu-
man MS4A3 gene (transcript variant 1, NM_006138.4)
was amplified using cDNA from U937_vec cells, the
primers listed in Additional file 5: Table S2, and Phusion
High Fidelity Polymerase (New England Biolabs, Ipswich,
MA, USA). PCR products were cloned into the retroviral
vector pMIA-II_IRES-Ametrine using the BamHI and
XhoI sites to yield pMIA-II_MS4A3-IRES-Ametrine.
DNA sequencing was performed to confirm the identity
and accuracy of the insert. Retroviral particles were gener-
ated and U937_EVI1 and U937_vec cells were infected
using standard procedures. After 3 days, cells were sorted
for Ametrine positivity on a FACS Aria (Becton Dickinson,
Franklin Lakes, NJ, USA). MS4A3 expression was con-
firmed by immunofluorescence analysis (IF). In brief, cells
were transferred onto cover slips coated with Cell-Tak™
Cell and Tissue Adhesive (Corning Incorporated, Corning,
NY) and fixed with ice-cold methanol (Roth, Karlsruhe,
Germany). IF was performed using rabbit polyclonal
MS4A3 antibody HPA019210 (Atlas Antibodies; dilu-
tion 1:30) and the Rhodamine (TRITC)-AffiniPure F(ab′)
2 Fragment Goat Anti-Rabbit IgG (H + L) secondary anti-
body (Jackson ImmunoResearch, West Grove, PA, USA;
dilution 1:200).UCSD-AML1 cells [56] were maintained in RPMI
1640 supplemented with 20% FBS, 1% PSG, and 10 ng/ml
GM-CSF (PeproTech, Rocky Hill, NJ). 2.25 × 106 cells
from a logarithmically growing culture were resus-
pended in 400 μl of PBS and electroporated either with a
mix of EVI1 siRNAs (stealth siRNAs HSS103423 and
HSS103424, Invitrogen) or with scrambled control siRNA
(stealth siRNA 462001, Invitrogen) at final concentrations
of 100 nM. Electroporation was carried out in a Gene
Pulser Xcell Electroporation System (BioRad, Hercules,
CA) at 300 V and 1000 μF using an exponential proto-
col. Electroporated cells were incubated under standard
growth conditions for 24 h prior to RNA extraction.
Gene expression microarrays and statistical and
bioinformatics analyses
For gene expression microarray analyses, U937T_EVI1-
HA E10 and U937T_EVI1-HA E14 cells were washed
and placed into media with or without tetracycline for 6,
12, 24, and 48 h. To control for potential effects of tetra-
cycline removal in the absence of EVI1 induction, U937T_
vec P2 and U937T cells incubated in the presence or ab-
sence of tetracycline for 48 h were also included in the
experiment. Total RNA was extracted using the RNeasy
kit (Qiagen, Hilden, Germany) as recommended by the
manufacturer. RNA quality control, sample labelling and
hybridization to Affymetrix HG-U133 plus 2.0 microar-
rays (Affymetrix, Santa Clara, CA, USA) were performed
at the Center of Excellence for Fluorescent Bioanalytics
(KFB; Regensburg, Germany). Robust Multi-array Analysis
was used for background correction, quantile normalization
and median polish summarization of probe levels. Only
probe sets with a current gene annotation and with average
log2-intensities ≥3 at 24 and 48 h in E10 and E14, and at
48 h in P2 and U937T cells, were included in downstream
analyses. Because we had previously observed background
effects of tetracycline withdrawal in control cells [53], probe
sets were considered as regulated by EVI1 only if they were
induced or repressed at least two-fold both at 24 and 48 h
after tetracycline withdrawal and both in E10 and E14
cells, and in addition the effect of tetracycline removal at
48 h in E10 and E14 cells was at least 10^(fold-change ex-
pression/3) the effect in the control cell lines P2 and
U937T. If more than one probe set for the same gene was
found to be regulated in this manner, the probe set with
the most pronounced regulation was included in the heat-
map, which was generated using Genesis [71]. All other
computational analyses and filtering procedures were per-
formed using R and custom PERL scripts. Microarray data
were deposited in the GEO database (accession number
GSE60100).
GO term enrichment was analysed using the term-for-
term algorithm of Ontologizer [72]. P-values were calcu-
lated using one-sided Fisher exact test, and adjusted for
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Hochberg [73]. An adjusted p-value <0.1 was considered
statistically significant.
GEO datasets GSE6891 [57], GSE14471 [58], and GSE35784
[59], which contain gene expression data from primary
AML samples, were probed for differences in MS4A3 ex-
pression between samples with high or low levels of EVI1
by bootstrap analysis. To determine cutoff values defining
high versus low EVI1 expression, the density distributions
of the log2 transformed EVI1 mRNA levels were estimated
using a Kernel Density Estimator (KDE). The EVI1 ex-
pression values at which the density distribution exhibited
a minimum were used as cutoffs for the respective data
set. In datasets where several local minima existed, the
minimum closest to the EVI1low distribution with <5% of
the maximal density defined the cutoff. The respective
groups of EVI1high patients were compared to randomly
sampled, equally sized groups of EVI1low patients. 10.000
iterations of this setup were performed, and in each step
the difference between the mean log2 transformed MS4A3
expression values in both groups was calculated. Finally,
the mean value of the resulting distribution (log2-fold
change, M) and the two-sided P-value using the inverse
standard normal cumulative distribution function were
determined.
Differences in MS4A3 expression between human
myeloid cell lines with high or low EVI1 mRNA levels
as represented in GEO data set GSE35159 [54] were
probed for significance by the CyberT algorithm of
Flexarray software (http://www.gqinnovationcenter.com/
downloads/index.aspx?l=e).
To predict potential binding sites of EVI1 in the MS4A3
promoter, 19 different position frequency (weight) matri-
ces (PWMs) were newly compiled or derived from experi-
mentally verified binding sites [38,39,61-67] or from the
Matbase matrix library 8.4 (Genomatix) and JASPAR [74]
databases. Potential EVI1 binding sites in the genomic re-
gion from -268 to -1 relative to the transcriptional start
site ofMS4A3 were identified based on a PERL implemen-
tation of the MatInspector algorithm [75] if the similarity
score for a specific PWM was equal to or above a thresh-
old that was defined by allowing one binding site per
10 kb of human coding sequences. Genomic sequences
were derived from the UCSC genome browser [76].
qRT-PCR
Total RNA for qRT-PCR was extracted using Trizol (Life
Technologies) and reverse transcribed using random
hexamer primers (Life Technologies) and M-MLV re-
verse transcriptase (Life Technologies) according to the
manufacturer’s instructions. qRT-PCR was carried out in a
Step One Plus Real Time PCR system (Applied Biosystems,
Life Technologies) using standardized cycling conditions
as recommended by the manufacturer. Levels of EVI1,MS4A3, and the housekeeping gene Cyclophilin D were
determined using the primers listed in Additional file 5:
Table S2 and the Mesa Green qPCR MasterMix Plus
(Eurogentec, Eraing, Belgium). All assays were performed
in triplicate. Expression values for the gene of interest
relative to the housekeeping gene and to a reference value
were determined using the ΔΔCT method [77]. At least
three biological replicates were analysed and mean fold
changes in expression and standard errors of the mean
(SEM) were calculated.
Reporter vectors and luciferase assays
All vectors used for luciferase assays were based on
pGluc basic (New England Biolabs). The MS4A3 5′ re-
gion (-3213/+11 relative to the transcription start site of
NM_006138) was amplified from human genomic DNA
using Phusion® High-Fidelity DNA Polymerase (New
England Biolabs) and the primers listed in Additional
file 5: Table S2. The resulting PCR product was ligated to
the EcoRV digested vector, yielding pMS4A3(-3213/+11)/
pGluc. A series of 5′ deletion constructs (-1992/-1, -1441/-
1, -1118/-1, -668/-1, -268/-1 and -3213/-279) was generated
by PCR amplification using the cloned promoter fragment
MS4A3(-3213/+11) as a template, followed by subcloning
using EcoRI and BamHI restriction enzymes (Fermentas
Inc., Hanover, MD, USA).
pMS4A3(-3213/+11)/tk/pGluc, pMS4A3(-268/-1)/tk/
pGluc, and pMS4A3(-3213/-279)/tk/pGluc were gener-
ated by subcloning the HSV tk promoter into the
BamHI, or the KpnI and BamHI, sites of the respective
pGluc basic based constructs.
For luciferase assays, 6 × 105 U937 cells/well were seeded
into 12-well plates. Transient transfections of reporter con-
structs and either empty pcDNA3 (Life Technologies) or
pcDNA3-EVI1 (containing a codon optimized version of
the human EVI1 cDNA) were performed using 1 μg DNA
(reporter:effector ratio = 1:3) and 4 μl of JetPEI cationic
polymer transfection reagent (Polyplus, Illkirch, France)
according to the manufacturer’s instructions. After 48 h,
50 μl of culture supernatant were mixed with 50 μl of Gluc
assay solution from the BioLux® Gaussia Luciferase Flex
Assay Kit (New England Biolabs). The bioluminescent re-
action was measured immediately by detecting the emit-
ted photons at 475 nm using a Tristar LB941 (Berthold
Technologies, Bad Wildbad, Germany). The values repre-
sent means + SEMs of three independent experiments.
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed using the chromatin immu-
noprecipitation assay kit (Upstate Biotechnology, Lake
Placid, NY, USA) as reported previously [78]. In brief,
5 × 106 U937_EVI1 or U937_vec cells were fixed by treat-
ment with 1% formaldehyde for 10 min and then lysed.
Chromatin was sheared to fragments of 200 - 1000 bp
Heller et al. Journal of Hematology & Oncology  (2015) 8:28 Page 11 of 14using Bioruptor (Diagenode, Liege, Belgium). Immunopre-
cipitation was performed using rabbit monoclonal EVI1
antibody C50E12 (Cell Signaling, Danvers, MA, USA; di-
lution 1:80) or rabbit polyclonal EVI1 antibody sc-8707X
(Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:250).
Nonspecific IgG (2729, Cell Signaling, 1:200) was used
as a negative control. Immunoprecipitated DNA was ex-
tracted with phenol/chloroform (Sigma-Aldrich), precipi-
tated with ethanol, and dissolved in 30 μl Tris-EDTA buffer
(Sigma-Aldrich). 2 μl of recovered DNA were subjected to
PCR analysis using the primers shown in Additional file 5:
Table S2 and HotStarTaq DNA Polymerase (Qiagen). Cyc-
ling conditions were: 95°C for 12 min, followed by 32 cycles
at 95°C for 30 s, 60°C for 40 s, and 72°C for 30 s, and a final
incubation step at 72°C for 7 min. PCR products were sepa-
rated on a 2% agarose gel stained with GelRed (Biotium,
Hayward, CA, USA).
Analyses of myelomonocytic differentiation and of cell
cycle distribution
To analyse myelomonocytic differentiation of U937 cells,
logarithmically growing cells were seeded to a density of
2 × 105 cells/ml and incubated either with 100 nM 25-
OH-Vitamin D3 (Calbiochem, La Jolla, CA) or with an
equivalent amount of solvent (EtOH) for 5 days. Cells
were diluted once during this period to avoid saturating
densities, and fresh 25-OH-Vitamin D3 was added at
the same time. After blocking of nonspecific epitopes
with Human TruStain (Biolegend, San Diego, CA), cells
were stained with monoclonal rat APC-Cy7 conjugated
CD11b antibody (clone M1/70, Biolegend) or corresponding
isotype control (clone RTK4530, Biolegend) using standard
procedures. Flow cytometric analysis was performed on an
LSRFortessa™ SORP (BD Biosciences, Bedford, MA, USA).
For cell cycle analyses, cells were adjusted to a density
of 400 cells/μl. On the next day, cells were washed with
PBS (Life Technologies) and incubated for 5 min in ice
cold 0.5 M citrate/0.5% Tween-20. Cell membranes were
disrupted mechanically before nuclei were pelleted
and resuspended in PBS containing 100 μg/ml RNase A
(Sigma-Aldrich) and 50 μg/ml propidium iodide (PI; Sigma-
Aldrich). Nuclear DNA content was determined on a
FACSCalibur™ (BD Biosciences) or a FACS LSRFortessa™
SORP using ModFit software (Verity Software House,
Topsham, ME, USA) for data analysis.
Xenograft experiments and immunohistochemistry
Animal experiments were approved by the ethics
committee of the Medical University of Vienna and the
Bundesministerium für Wissenschaft und Forschung Ref.
II/10b (Gentechnik und Tierversuche), application Nr.
BMWF-66.009/0095-II/10b/1010, and were carried out
according to the Austrian and FELASA guidelines for ani-
mal care and protection in order to minimize distressfor the animals. Mice were sacrificed by cervical
dislocation.
Six to eight week old male CB-17 scid/scid (SCID) mice
were purchased from Harlan Laboratories (San Pietro al
Natisone, Italy). The animals were kept in a pathogen-free
environment and all procedures were performed in a lam-
inar airflow cabinet. 5 × 106 U937_vec_vec, U937_vec_
MS4A3, U937_EVI1_vec, or U937_EVI1_MS4A3 cells, re-
suspended in 50 μl of serum-free RPMI 1640 medium,
were injected subcutaneously into the right flanks of 4
mice per cell line. Animals were controlled every day
and tumor size was assessed regularly by caliper meas-
urement. Tumor volume was calculated using the for-
mula: (length × width2)/2. At experiment termination,
mice were dissected and tumor tissue was processed for
immunohistochemistry (IHC). For statistical analysis of
tumor growth, two-way ANOVA and Bonferroni post-
correction were applied.
IHC was performed using standard procedures. Briefly,
4 μm sections from xenograft tumor blocks were depar-
affinized and rehydrated, heated for 10 min in 10 mM
citrate buffer (pH 6.0) in a pressure cooker for epitope re-
trieval, and then incubated for 60 min at room temperature
with rabbit monoclonal EVI1 (clone C50E12, Cell Signaling
Technology; dilution 1:200) or rabbit polyclonal MS4A3
(HPA019210, Atlas Antibodies; dilution 1:50) antibodies, or
for 30 min with mouse monoclonal Ki-67 antibody (MIB-1,
Dako, Glostrup, Denmark; dilution 1:100). Antibody bind-
ing was detected by means of the UltraVision LP de-
tection system (Lab Vision, Thermo Fisher Scientific,
San Jose, CA, USA) according to the manufacturer’s
recommendations. Color development was performed by
3-3′-diaminobenzidine (Dako) and counterstaining by
hematoxylin (Merck, Vienna, Austria). Terminal deoxynu-
cleotidyl transferase dUTP nick end labeling (TUNEL)
was carried out using the in situ cell death detection kit,
TMR Red (Roche, Mannheim, Germany) according to the
manufacturer’s instructions.
Images of stained tumor sections were acquired with
TissueFAXS (TissueGnostics, Vienna, Austria). Percent-
ages of TUNEL-positive cells were determined using Tis-
sueQuest software (TissueGnostics).Additional files
Additional file 1: Table S1. Gene Ontology (GO) categories
overrepresented among the genes regulated in response to induction of
EVI1 in U937T_EVI1-HA cells.
Additional file 2: Figure S1. Confirmation of ectopic expression of
MS4A3 in transduced U937_EVI1 and U937_vec cells. Immunofluorescence
analysis of MS4A3 expression in U937_vec_vec (A), U937_vec_MS4A3 (B),
U937_EVI1_vec (C), and U937_EVI1_MS4A3 (D) cells. Endogenous MS4A3
was observed in U937_vec_vec and U937_EVI1_vec cells, and strong
ectopic MS4A3 expression was present in U937_vec_MS4A3 and
U937_EVI1_MS4A3 cells.
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myelomonocytic differentiation of U937 cells, but ectopic expression of
MS4A3 has no impact on this process. U937_vec_vec, U937_vec_MS4A3,
U937_EVI1_vec, and U937_EVI1_MS4A3 cells were treated with EtOH
(solvent) or 25-OH Vitamin D3 for 5 days, and the extent of myelomonocytic
differentiation was determined by flow cytometry after staining for CD11b.
(A) Histograms from a representative experiment. Blue areas, isotype
control antibody; red areas, APC-Cy7 conjugated CD11b antibody.
(B) Summary of flow cytometric data from three independent biological
replicate experiments. Mean percentages of positive cells + SEMs are shown.
***p <0.001; (Student’s t-test, two-tailed).
Additional file 4: Figure S3. Nuclear localization of Ki-67 and of double
strand break containing DNA identified through TUNEL staining.
Magnifications from one of the tumors shown in Figure 4B. (A)
Immunohistochemical staining for Ki-67; (B) TUNEL staining. Scale bar, 50 μm.
Additional file 5: Table S2. Oligonucleotide primers used for cDNA
cloning, qRT-PCR, preparation of reporter constructs, and ChIP. fwd,
forward primer; rev, reverse primer.
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